Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Myles Minter

Argenx Beats Sales Expectations — But Not By Enough — And Shares Tumble

Argenx stock tumbled Thursday after the company's autoimmune disease drug, Vyvgart, beat first-quarter sales forecasts — but not by enough.

Investors Business Daily

Argenx Bounds Off 200-Day Line On 'Best-Case Scenario' For Blockbuster Drug

Argenx stock jumped Friday after the FDA cleared its autoimmune disease drug, Vyvgart Hytrulo, for at-home treatment.

Investors Business Daily

Moderna and Novavax shares plunge after key FDA official steps down, citing discord with RFK Jr. who he says 'wishes subservient confirmation of his misinformation and lies'

Massive cuts to personnel and funding within the Department of Health and Human Services presents a headache for vaccine approval and development, analysts say.

Fortune

From analysis to the latest developments in health,
read the most diverse news in one place.

IBD 50's Axsome Therapeutics Dives On Mixed ADHD Results. Why Analysts Aren't Worried.

Axsome stock tumbled Tuesday after Axsome Therapeutics issued mixed results for its drug, Sunosi, in ADHD treatment.

Investors Business Daily

How Painkillers Could Be Vertex Pharmaceuticals' Next $10 Billion Chapter

Vertex Pharmaceuticals could soon capture $10 billion in sales of non-opioid painkillers, an analyst said Friday as Vertex stock jumped.

Investors Business Daily

Moderna's Pain Continues Amid Flurry Of Downgrades Following 'Tough' R&D Day

Moderna stock tumbled again Friday on a series of downgrades and price-target cuts following a "tough update" at its R&D Day.

Investors Business Daily

Axsome Dips On Wide Losses, But Its Biggest Moneymaker Tacks On 135% Growth

Axsome stock fell Monday after the company posted wider-than-expected losses, though second-quarter sales depression drug beat most views.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

FDA Panelists Unanimously Back Eli Lilly's Biogen-Rivaling Alzheimer's Drug

Eli Lilly stock jumped Monday after FDA advisors said the benefits of Alzheimer's treatment donanemab outweigh the risks for most patients.

Investors Business Daily

Moderna Wins FDA Approval For Second-Ever Product; Why Its RSV Vaccine Could Dominate Pfizer, GSK

The FDA approved Moderna's RSV vaccine, allowing the biotech to launch its second-ever product. But Moderna stock retreated.

Investors Business Daily

Here's Why IBD Stock Of The Day Vertex Pharmaceuticals Is Newly Actionable

Vertex is the IBD Stock Of The Day. VRTX stock bounced off its 50-day line as investors watch for the first sales of its gene-editing drug.

Investors Business Daily

The $660 Million Opportunity That's Driving IBD Stock Of The Day Neurocrine Biosciences Higher

Neurocrine is Tuesday's IBD Stock Of The Day. After it unveiled promising results for a genetic disease drug, NBIX stock is on the rise.

Investors Business Daily

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Vertex Pharmaceuticals

184 stories

VRTX

163 stories

the Department of Health and Human Services

118 stories

Eisai

95 stories

Neurocrine Biosciences

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.